| Joel Kent Van De Graaff, MD | |
|
Emile @ 42nd St, Omaha, NE 68198-2055 | |
| (402) 559-4015 | |
| (402) 559-8715 |
| Full Name | Joel Kent Van De Graaff |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 13 Years |
| Location | Emile @ 42nd St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326333220 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unmc Physicians | 6002728391 | 1320 |
News Archive
HealthSouth Corporation announced today that it plans to build a 50-bed comprehensive inpatient rehabilitation hospital in Newnan, Ga.
According to a new study published in the Journal of the Royal Society of Medicine, the carbon footprint of personal protective equipment (PPE) provided to health and social care staff in England during the first six months of the COVID-19 pandemic was equivalent to flying from London to New York 244 times every day.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research.
› Verified 2 days ago
| Entity Name | Unmc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
HealthSouth Corporation announced today that it plans to build a 50-bed comprehensive inpatient rehabilitation hospital in Newnan, Ga.
According to a new study published in the Journal of the Royal Society of Medicine, the carbon footprint of personal protective equipment (PPE) provided to health and social care staff in England during the first six months of the COVID-19 pandemic was equivalent to flying from London to New York 244 times every day.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel Kent Van De Graaff, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: () - | Joel Kent Van De Graaff, MD Emile @ 42nd St, Omaha, NE 68198-2055 Ph: (402) 559-4015 |
News Archive
HealthSouth Corporation announced today that it plans to build a 50-bed comprehensive inpatient rehabilitation hospital in Newnan, Ga.
According to a new study published in the Journal of the Royal Society of Medicine, the carbon footprint of personal protective equipment (PPE) provided to health and social care staff in England during the first six months of the COVID-19 pandemic was equivalent to flying from London to New York 244 times every day.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research.
› Verified 2 days ago
Sara Michelle May, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: Emile 42nd St, Omaha, NE 68198 Phone: 402-559-4015 Fax: 402-559-8715 | |
Mr. Roger Hiro Kobayashi, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2808 S 80 Ave, Ste 210, Omaha, NE 68124 Phone: 402-391-1800 Fax: 402-391-1563 | |
Dr. Againdra K Bewtra, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 601 N 30th St Ste 5730, Omaha, NE 68131 Phone: 402-280-4403 | |
Dr. Jaine Brownell, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 16945 Frances St, Omaha, NE 68130 Phone: 402-397-7400 Fax: 402-397-0115 | |
Mr. Brett Van Kettelhut, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2808 S 80 Ave, Ste 210, Omaha, NE 68124 Phone: 402-391-1800 Fax: 402-391-1563 | |
Dr. Teodoro Segura, MD, PHD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 16945 Frances St, Omaha, NE 68130 Phone: 402-397-7400 Fax: 402-397-0115 |